Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma

Clinical Trial ID NCT00887107

PubWeight™ 4.38‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00887107

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009 1.78
2 Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab 2010 1.72
3 Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma. PLoS One 2012 0.92
Next 100